This study was to investigate the efficacy and safety of regorafenib or fruquintinib combined with camrelizumab in patients with microsatellite stable (MSS) and/or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC).Medical records of MSS/pMMR mCRC patients who received regorafenib (80 mg) or fruquintinib (3 mg) once a day (21 days on/7 days off) plus camrelizumab (200 mg) every three weeks in Yuhuangding Hospital between January 2020 and June 2020 were retrospectively collected.Follow-up data up to November 1st, 2020 was gathered. The primary endpoint was the objective response rate (ORR) and disease control rate (DCR). The safety profile was the secondary endpoint.A total of 16 patients were enrolled. The ORR was 25.0% (4/16) and the DCR was 62.5% (10/16).The main adverse events (AEs) included reactive cutaneous capillary endothelial proliferation (RCCEP) (81.3%), fatigue (43.8%), hypertension (37.5%), hand-foot skin reaction (25.0%), and thyroid dysfunction (25.0%). Most AEs were grade 1 or 2, with only 1 patient of grade 3 liver dysfunction. All the AEs were ameliorated by effective symptomatic treatment.Regorafenib or fruquintinib plus camrelizumab exhibited promising efficacy in patients with MSS/pMMR mCRC. The toxicity was moderate and manageable.
N6-methyladenosine (m6A) is the most prevalent type of RNA modification, and we hypothesized that patterns of m6A-related genes may be useful for estimating risk of lung adenocarcinoma (LUAD). An m6A-related gene set variation score (m6A-GSVS) was generated using RNA-sequencing data from LUAD patients in The Cancer Genome Atlas (TCGA). We investigated the association of m6A-GSVS with stemness, tumor mutational burden (TMB), expression of three immune checkpoints, levels of tumor-infiltrating lymphocytes (TILs), and patient prognosis. We found that m6A-GSVS was higher in LUAD than in healthy lung tissue, and it strongly correlated with stemness and TMB. Activated CD4 + T cells were more numerous in LUAD samples that had higher m6A-GSVS than in those with lower scores. Biological processes and pathways, including “Cell cycle,” “DNA replication,” and “RNA degradation,” were significantly enriched in samples with high scores. Furthermore, m6A-GSVS was an independent prognostic indicator in LUAD. In conclusion, we proposed an m6A-GSVS in LUAD. It is a putative indicator for evaluating the ability to RNA m6A, an independent prognostic indicator and associated with tumor stemness.
The present study compared the dosimetric differences of volumetric modulated arc therapy (VMAT) and 7-field intensity modulated radiation therapy technology (7F-IMRT) in assisted radiotherapy plan after resection of rectal carcinoma. Ten cases of patients at stages II–III of rectal cancer transabdominal resection with postoperative pelvic radiotherapy underwent 7F-IMRT and VMAT radiotherapy plan design using the CMS Monaco treatment planning system. We compared the dose distribution, the number of organs at risk and the number of machines in the two groups. The 7F-IMRT plans conformal index (CI) was 0.8319±0.0143 and VMAT plans CI was 0.838±0.164. Both plans reached up to the 95% isodose line at a volume of 100% planning target volume (PTV), the 7F- IMRT plans homogeneity index (HI) was 1.0760±0.0179, and the VMAT plans HI was 1.0821±0.0143. CI and HI had no statistical difference. With regard to S40, the V50 dose volume of the small intestine was endangered, and the VMAT plan was better than that of the 7F-IMRT plan, and the difference was statistically significant (P<0.05). The machine hop numbers of the two types of plans were 594.1±36.1 and 793.2 ±56.6 for for VMAT and 7F-IMRT, respectively. The VMAT plan was less than htat of the 7F-IMRT and the difference was statistically significant (P<0.05). Patients to whom VMAT techniques were utilized after resection of rectal cancer obtained an equal or a superior dose distribution compared with the IMRT plan. VMAT had important significance in protecting the small intestine, while significantly reducing treatment time.
Background and objectivesBreast cancer is one of the most common causes of cancer-related deaths in women worldwide. Studies on glucosylceramide synthase (GCS) activity suggest that this enzyme has a role in the development of multidrug resistance in many cancer cells. However, few studies have shown the expression of GCS in invasive ductal breast cancer and breast intraductal proliferative lesions.MethodsIn total, 196 samples from patients with invasive ductal breast cancer and 61 samples of breast intraductal proliferative lesions were collected. Immunohistochemical analyses were conducted to determine the expression of GCS and other related proteins.ResultsExpression of GCS was high in estrogen receptor (ER)-positive and HER-2 negative samples. In contrast, the expression of GCS in invasive ductal cancer was significantly lower than that in intraductal proliferative lesions.ConclusionOur data demonstrates a correlation between the expression of the GCS protein and ER-positive/HER-2 negative breast cancer. Furthermore, in contrast to previous reports, the expression of GCS protein was shown to be much higher in ductal carcinoma in-situ than that in invasive ductal cancer.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1559854430111589.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.